Health Affairs Study Deflects New Tech Cost Critics; JEC Report Forthcoming
This article was originally published in The Gray Sheet
Executive Summary
An article in the 1July/August issue of Health Affairs cites economic data from FDA Commissioner Mark McClellan to argue that thwarted access to new medical technologies among the uninsured yields $1.1 bil. in lost annual net benefits
You may also be interested in...
FDA, CMS Reviewers Appraise Cost Effectiveness; ICD Decision Scrutinized
Cost-effectiveness analyses represent an opportunity for greater FDA/CMS collaboration when the agencies review device trials for approval or reimbursement decisions, according to FDA Office of Device Evaluation Director Dan Schultz
Medical Technology Cost Awareness “Campaign” Led By Blues, Lewin Report
The BlueCross BlueShield Association intends to heighten consumer awareness of accelerating medical technology costs, which the group believes is a key driver of U.S. health expenditures in recent years
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.